Supernus Pharmaceuticals (SUPN) SVP reports 1,650 performance share units

Rhea-AI Filing Summary

Supernus Pharmaceuticals, Inc. executive Frank Mottola, SVP and Chief Technical Operations Officer, reported the acquisition of 1,650 Performance Share Units on July 29, 2026.

The units relate to an award granted on February 19, 2025 that vests upon achievement of individual performance objectives established on May 3, 2025. Following this transaction he holds 1,650 units directly, each corresponding to one share of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mottola Frank

Role SVP, Chief Tech. Ops. Officer

Type	Security	Shares	Price	Value
Grant/Award	Performance Share Unit F1	1,650	$0.00	$0.00

Holdings After Transaction: Performance Share Unit — 1,650 shares (Direct)

Footnotes (1)

1. F1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Key Figures

Performance Share Units acquired: 1,650 units Underlying common shares: 1,650 shares Total PSUs held after transaction: 1,650 units +2 more

5 metrics

Performance Share Units acquired 1,650 units Grant/award acquisition on July 29, 2026

Underlying common shares 1,650 shares Common stock underlying the Performance Share Units

Total PSUs held after transaction 1,650 units Direct holdings for Frank Mottola following the reported acquisition

PSU award date February 19, 2025 Date the Performance Share Units award was granted

Performance objectives set May 3, 2025 Date individual performance objectives for the PSUs were established

Key Terms

Performance Share Units, defined performance period, individual performance objectives

3 terms

Performance Share Units financial

"On February 19, 2025, the Reporting Person was awarded Performance Share Units"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

defined performance period financial

"vested upon the achievement of individual performance objectives within a defined performance period"

individual performance objectives financial

"a portion of which vested upon the achievement of individual performance objectives"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 05:05 PM Accepted by SEC EDGAR 07/31/2026 - 05:05 PM Learn about SEC filing dates

FAQ

What insider transaction did Supernus Pharmaceuticals (SUPN) report for Frank Mottola?

Supernus Pharmaceuticals reported that Frank Mottola acquired 1,650 Performance Share Units on July 29, 2026. These units relate to a February 19, 2025 award and are settled in common stock based on individual performance objectives.

How many Performance Share Units did Frank Mottola receive in the latest SUPN Form 4?

The filing shows that Frank Mottola received 1,650 Performance Share Units. These derivative awards are tied to Supernus common stock, with 1,650 underlying shares reported, reflecting a one-to-one relationship between units and shares.

When were the Performance Share Units in SUPN's filing originally awarded and how do they vest?

The Performance Share Units were awarded on February 19, 2025. They vest upon the achievement of individual performance objectives within a defined performance period, with those objectives established on May 3, 2025, according to the footnote disclosure.

What does each of Frank Mottola's Performance Share Units at Supernus represent?

Each Performance Share Unit represents the right to receive one share of Supernus common stock. The filing reports 1,650 underlying common shares for the 1,650 units credited to Frank Mottola in this transaction.

What is Frank Mottola's reported Performance Share Unit holding in SUPN after this transaction?

After the reported transaction, Frank Mottola holds 1,650 Performance Share Units directly. The total shares following the transaction are listed as 1,650 units, matching the number of underlying Supernus common shares associated with this award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mottola Frank

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Tech. Ops. Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	07/29/2026		A		1,650		(1)	(1)	Common Stock	1,650	$0	1,650	D

Explanation of Responses:

1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)